To understand the role of corticosteroid-binding globulin (CBG) in the intracellular steroidal actions in human ovarian cancers, the level of CBG mRNA expression was evaluated in normal ovarian tissues and in ovarian cancers using competitive reverse transcription-polymerase chain reaction-Southern blot analysis. The expression of CBG mRNA was detected in all normal ovaries and ovarian cancers analyzed. There were no significant differences in the mean CBG mRNA levels between normal ovaries and ovarian cancers. The expression in normal ovaries was significantly higher (p < 0.01) in the premenopause than in the postmenopause. A high expression of CBG mRNA was observed in 11 out of 29 cases (38%) of ovarian cancer in comparison with normal ovaries. There was no difference in the expression among the histological classifications or clinical stages of ovarian cancers. These data suggest that human normal ovaries and ovarian cancers might synthesize CBG intracellularly, ovarian cancers might conserve a progesterone-associated property via CBG, and the regulation of intracelluar CBG expression might be changed in some cancers.

Keywords:
Corticosteroid-binding globulin, Ovarian cancer, mRNA
This content is only available via PDF.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.